Back to Search
SOFIA MERAJVER, MD, PHD
MD, PHD
Medical Oncology Physician
NPI: 1568548428IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
4301053252(MI)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
4301053252(MI)
Education
OTHER
Class of 1987
Research & Publications (20)
Multifaceted role of Rho proteins in angiogenesis.
PMID 16900393·J Mammary Gland Biol Neoplasia·2005
6-review
Urban-rural differences in breast cancer incidence by hormone receptor status across 6 years in Egypt.
PMID 19548084·Breast Cancer Res Treat·2010
8-other
Xenoestrogens may be the cause of high and increasing rates of hormone receptor positive breast cancer in the world.
PMID 19155145·Med Hypotheses·2009
8-other
Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.
PMID 19351752·Clin Cancer Res·2009
3-trial
Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm.
PMID 19335282·Expert Opin Investig Drugs·2009
1-meta
Analysis of RhoC expression and lymphovascular emboli in inflammatory vs non-inflammatory breast cancers in Egyptian patients.
PMID 19157876·Breast·2009
4-observational
Breast cancer characteristics at diagnosis and survival among Arab-American women compared to European- and African-American women.
PMID 18415013·Breast Cancer Res Treat·2009
4-observational
Deleterious CHEK2 1100delC and L303X mutants identified among 38 human breast cancer cell lines.
PMID 18297428·Breast Cancer Res Treat·2009
8-other
Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1.
PMID 19079346·Oncogene·2009
7-preclinical
A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer.
PMID 18712502·Invest New Drugs·2009
3-trial
Preclinical development of a bifunctional cancer cell homing, PKCepsilon inhibitory peptide for the treatment of head and neck cancer.
PMID 19567682·Cancer Res·2009
7-preclinical
Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia.
PMID 19661437·Am J Pathol·2009
7-preclinical
Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1.
PMID 18321996·Am J Pathol·2008
8-other
A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results.
PMID 18640301·Ann Thorac Surg·2008
3-trial
RhoA-GDP regulates RhoB protein stability. Potential involvement of RhoGDIalpha.
PMID 18524772·J Biol Chem·2008
7-preclinical
Molecular determinants of the inflammatory breast cancer phenotype.
PMID 19198217·Oncology (Williston Park)·2008
8-other
BRCA1 regulates human mammary stem/progenitor cell fate.
PMID 18230721·Proc Natl Acad Sci U S A·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1500 E MEDICAL CENTER DR
ANN ARBOR, MI 48109 - Phone
- (734) 936-4000
Quick Facts
- NPI
- 1568548428
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 39
- Publications
- 20
Are you this provider?
Claim Your Profile